»êµ¿ ½ÃÀå : ¼¼°è ¹× Áö¿ªº° ºÐ¼® - ºÐ¼®°ú ¿¹Ãø(2025-2035³â)
Mydriasis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
»óǰÄÚµå : 1759272
¸®¼­Ä¡»ç : BIS Research Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,900 £Ü 6,745,000
PDF and Excel (1-3 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 3¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,500 £Ü 10,325,000
PDF and Excel (Global License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

»êµ¿À̶õ µ¿°øÀÌ ºñÁ¤»óÀûÀ¸·Î Ä¿Áö´Â µ¿°ø»ê´ëÁõÀ» ÀÏÄ´ ÀÇÇпë¾îÀÔ´Ï´Ù.

»êµ¿Àº ºûÀÌ ºÎÁ·ÇÑ »óȲ(¾È±¸¿¡ ¸¹Àº ºûÀ» ¹Þ¾ÆµéÀ̱â À§ÇØ)¿¡ ´ëÇÑ ¹ÝÀÀÀ¸·Î ÀÚ¿¬ÀûÀ¸·Î ¹ß»ýÇϱ⵵ Çϰí, ÀÇÇÐÀû ÀÌÀ¯·Î À¯¹ßµÇ±âµµ ÇÕ´Ï´Ù. »êµ¿Àº ¸Á¸·, ½Ã½Å°æ ¹× ±âŸ ¾È±¸ ³» ±¸Á¶¸¦ ´õ ¼±¸íÇÏ°Ô º¸±â À§ÇØ ¾È°ú °Ë»ç¿¡¼­ ÀǵµÀûÀ¸·Î »ç¿ëµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ³ì³»Àå, ´ç´¢¸Á¸·º´Áõ, ³ëÀÎȲ¹Ýº¯¼º(AMD) µî ´Ù¾çÇÑ ¾ÈÁúȯÀÇ Áø´Ü¿¡ ÇʼöÀûÀÔ´Ï´Ù.

»êµ¿Àº Æ®·ÎÇÇÄ«¹Ìµå, Æä´Ò¿¡ÇÁ¸°, ¾ÆÆ®·ÎÇɰú °°Àº »êµ¿Á¦¸¦ »ç¿ëÇÏ¿© À¯¹ßÇÒ ¼ö ÀÖÀ¸¸ç, µ¿°ø ÁÖÀ§ÀÇ ±ÙÀ°À» À̿ϽÃŰ°í µ¿°øÀ» È®Àå½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀϹÝÀûÀ¸·Î ÀϽÃÀûÀÎ Áõ»óÀÌÁö¸¸, ½Å°æÁúȯ, ¾È±¸ ¿Ü»ó, ƯÁ¤ ¾à¹°ÀÇ ¿µÇâÀ¸·Î »êµ¿ÁõÀÌ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù.

»êµ¿ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â ÷´Ü ¾È°ú Áø´Ü ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù. ¾ÈÀú Ä«¸Þ¶ó, ±¤°£¼·´ÜÃþÃÔ¿µ±â(OCT), ¸Á¸· ¿µ»ó ½Ã½ºÅÛ µî ÀÇ·á¿ë ¿µ»óó¸® ½Ã½ºÅÛÀÌ Áö¼ÓÀûÀ¸·Î °³¼±µÇ°í ÀÖ´Â °¡¿îµ¥, ÃÖÀûÀÇ ¼º´ÉÀ» ¹ßÈÖÇϱâ À§Çؼ­´Â Á¤È®ÇÑ µ¿°ø È®ÀåÀÌ ÇÊ¿äÇÕ´Ï´Ù.

ÀÌ·¯ÇÑ ±â¼úÀº ³ì³»Àå, ´ç´¢¸Á¸·º´Áõ, Ȳ¹Ýº¯¼º µî ´Ù¾çÇÑ ¾ÈÁúȯÀÇ Áø´Ü¿¡ ÇʼöÀûÀÎ ¸Á¸·, ½Ã½Å°æ ¹× ±âŸ Áß¿äÇÑ ¾È±¸ ³» ±¸Á¶¹°ÀÇ °íÇØ»óµµ ¿µ»óÀ» Á¦°øÇÕ´Ï´Ù. »êµ¿Àº ÀÌ·¯ÇÑ Áø´Ü ½Ã ¼±¸íÇϰí Á¤È®ÇÑ ¿µ»óÀ» ¾ò±â À§ÇØ ¸Å¿ì Áß¿äÇϸç, µ¿°ø »êµ¿À» À¯µµÇÏ´Â »êµ¿Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áø´Ü µµ±¸°¡ º¸±ÞµÇ°í È¿À²¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó »êµ¿Á¦ ¼ö¿ä´Â °è¼Ó Áõ°¡ÇÏ¿© »êµ¿Á¦ ½ÃÀå È®´ë¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¸¼º ¾ÈÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ¼¼°è Àα¸ÀÇ °í·ÉÈ­´Â Á¤±âÀûÀÎ ¾È°ú °Ë»ç¿¡¼­ µ¿°ø »êµ¿¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ºÎÃß°Ü »êµ¿À» Çö´ë ¾È°ú ÀÇ·áÀÇ Áß¿äÇÑ ¿ä¼Ò·Î ¸¸µé°í ÀÖ½À´Ï´Ù.

»êµ¿Á¦ ½ÃÀåÀÇ ¼ºÀå¿¡µµ ºÒ±¸ÇÏ°í ¸î °¡Áö °úÁ¦°¡ ±× ¹ßÀüÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä °úÁ¦ Áß Çϳª´Â »êµ¿Á¦¿Í °ü·ÃµÈ ºÎÀÛ¿ë°ú ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·ÁÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°Àº Áø´Ü ¸ñÀûÀÇ µ¿°ø È®Àå¿¡ È¿°úÀûÀÌÁö¸¸, ´«ÀÇ ºÒÆí°¨, ¾È¾Ð »ó½Â, ±¤°ú¹ÎÁõ(ºû¿¡ ´ëÇÑ °ú¹ÎÁõ), ¾È°³°¡ ³¤ ½Ã¾ß¸¦ À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. °æ¿ì¿¡ µû¶ó¼­´Â ½É¹Ú¼ö Áõ°¡, °íÇ÷¾Ð µî Àü½ÅÀûÀÎ ºÎÀÛ¿ëÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¸ç, ƯÈ÷ °íÇ÷¾ÐÀ̳ª ½ÉÇ÷°ü Áúȯ µî ±âÀúÁúȯÀÌ ÀÖ´Â »ç¶÷¿¡°Ô´Â ÁÖÀǰ¡ ÇÊ¿äÇÕ´Ï´Ù.

¶ÇÇÑ, °úµµÇÑ È®ÀåÀÇ À§Çèµµ ÀÖ¾î Áø´Ü °úÁ¤À» º¹ÀâÇÏ°Ô ¸¸µé°Å³ª ÈÄ¼Ó Ä¡·á Áß ºÎÀÛ¿ëÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀϺΠȯÀÚ, ƯÈ÷ ³ëÀΰú ´ç´¢º´ ¹× ³ì³»Àå ȯÀÚ´Â È®Àå °úÁ¤¿¡ ¾î·Á¿òÀ» °ÞÀ» ¼ö ÀÖÀ¸¸ç Ãß°¡ ¸ð´ÏÅ͸µ ¹× Á¶Á¤ÀÌ ÇÊ¿äÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ ¾ÈÀü¼º ¹®Á¦´Â ƯÈ÷ Ãë¾àÇÑ È¯ÀÚ Áý´Ü¿¡¼­ »êµ¿ ¾à¹°ÀÇ ±¤¹üÀ§ÇÑ »ç¿ëÀ» Á¦ÇÑÇϰí ÀϺΠ»êµ¿ Ä¡·áÀÇ Ã¤ÅÃÀ» Áö¿¬½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦´Â Áø´Ü ÀýÂ÷¿¡ ÇÊ¿äÇÑ ¼öÁØÀÇ µ¿°ø »êµ¿À» ´Þ¼ºÇϸ鼭µµ ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ´Â º¸´Ù ¾ÈÀüÇϰí È¿°úÀûÀÎ ´ëü ¾à¹°ÀÇ Çʿ伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

Viatris Inc., Opus Genetics, Eyenovia, Inc., Rayner Surgical Group Limited, Omeros Corporation, Omeros Corporation, Alcon Inc. Alcon Inc., Novartis AG, Pfizer Inc., Akorn, Inc., AbbVie Inc. µîÀÇ ±â¾÷µéÀº ¾È°ú Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ ±â¼ú ¹ßÀü°ú »êµ¿Á¦ °³¹ßÀÇ ÃÖÀü¼±¿¡ ¼­ ÀÖ½À´Ï´Ù.

ÀÌµé ±â¾÷Àº ¿¬±¸°³¹ß(R&D)¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, »êµ¿Ä¡·áÀÇ È¿°ú, ¾ÈÀü¼º, ȯÀÚ °æÇè °³¼±¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àü·«Àû Á¦ÈÞ, Àμö, Á¦Ç° Æ÷Æ®Æú¸®¿À È®ÀåÀ» ÅëÇØ °æÀï·ÂÀ» À¯ÁöÇÏ°í ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù. ¾ÈÀú Ä«¸Þ¶ó³ª ºû°£¼·´ÜÃþÃÔ¿µ(OCT)°ú °°Àº ¾È°ú À̹Ì¡ ±â¼úÀÌ °è¼Ó ¹ßÀüÇϰí ÀÖ´Â °¡¿îµ¥, ÀÌµé ±â¾÷Àº ¼¼°è ½ÃÀå¿¡¼­ »êµ¿ÁõÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀÔ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

¼¼ºÐÈ­ 1: Áö¿ªº°

¼¼°è »êµ¿ ½ÃÀåÀº ¾È°ú Áø´ÜÀÇ Àü¸ÁÀ» À籸¼ºÇÏ´Â ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÈûÀÔ¾î Å« º¯È­ÀÇ ½Ã±â¸¦ ¸ÂÀÌÇϰí ÀÖ½À´Ï´Ù. ù°, ¾ÈÀú Ä«¸Þ¶ó, ºû°£¼·´ÜÃþÃÔ¿µ(OCT) µî ¿µ»ó ±â¼úÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀº ¾È°ú Àǻ簡 ¸Á¸·°ú ½Ã½Å°æÀ» °Ë»çÇÏ´Â ¹æ½Ä¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úµéÀº °íÇØ»óµµÀÇ ¼¼¹ÐÇÑ ¿µ»óÀ» ÃÔ¿µÇϱâ À§ÇØ Á¤È®ÇÑ µ¿°ø È®ÀåÀÌ ÇÊ¿äÇϸç, ÀÌ´Â È¿°úÀûÀÎ »êµ¿Á¦ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

µÑ°, ³ì³»Àå, ´ç´¢¸Á¸·º´Áõ, ¹é³»Àå µî ¸¸¼º ¾ÈÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó »êµ¿°ú °ü·ÃµÈ Á¤±âÀûÀÎ Áø´Ü ÀýÂ÷ÀÇ Çʿ伺ÀÌ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼¼°è Àα¸ÀÇ °í·ÉÈ­¿¡ µû¶ó, ƯÈ÷ ¼±Áø±¹¿¡¼­´Â ¿µ±¸ÀûÀÎ ½Ã·Â ÀúÇϸ¦ ¿¹¹æÇϱâ À§ÇØ ÀÌ·¯ÇÑ ÁúȯÀ» Á¶±â¿¡ ¹ß°ßÇÏ°í °ü¸®ÇØ¾ß ÇÒ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ÀÇ·á Á¢±Ù¼º È®´ë´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¾Æ½Ã¾ÆÅÂÆò¾ç ¹× ¶óƾ¾Æ¸Þ¸®Ä« µîÀÇ Áö¿ª¿¡¼­´Â ÃֽŠÁø´Ü µµ±¸¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ¾î µ¿°øÈ®Àå¼úÀÌ ÇÊ¿äÇÑ ¾È°ú °Ë»ç¸¦ ¹Þ´Â ȯÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¸¶Áö¸·À¸·Î, ¾È°ú¿¡¼­ °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í Á¤¹Ð Áø´Ü¿¡ ´ëÇÑ Á߿伺ÀÌ ³ô¾ÆÁö¸é¼­ »êµ¿ Ä¡·áÀÇ ±â¼ú Çõ½ÅÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. °¢ ¾÷üµéÀº ȯÀÚ °³°³ÀÎÀÇ Çʿ信 µû¶ó º¸´Ù ¾ÈÀüÇϰí Áï°¢ÀûÀÎ È¿°ú¸¦ ¹ßÈÖÇÏ´Â »êµ¿Á¦¸¦ °³¹ßÇÏ¿© º¸´Ù È¿À²ÀûÀÌ°í Æí¾ÈÇÑ ¾È°ú °Ë»ç¸¦ ½ÇÇöÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ¸ðµÎ »êµ¿ ½ÃÀåÀÇ Áö¼ÓÀûÀÎ º¯È­¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, »êµ¿ ½ÃÀåÀº ¼¼°è ÇコÄɾî ȯ°æ¿¡¼­ ¿ªµ¿ÀûÀÌ°í ºü¸£°Ô º¯È­ÇÏ´Â ºÐ¾ß°¡ µÇ°í ÀÖ½À´Ï´Ù.

¼¼°èÀÇ »êµ¿ ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÃâ ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

ÁÖ¿ä ¿ä¾à

Á¦1Àå ¼¼°èÀÇ »êµ¿ ½ÃÀå : ¾÷°è Àü¸Á

Á¦2Àå ¼¼°èÀÇ »êµ¿ ½ÃÀå(Áö¿ªº°), 2023³â-2035³â

Á¦3Àå ¼¼°èÀÇ »êµ¿ ½ÃÀå : °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦4Àå Á¶»ç ¹æ¹ý

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Mydriasis Market, Analysis and Forecast: 2025-2035

Mydriasis is a medical term that refers to the dilation of the pupil, where the pupil becomes abnormally enlarged. This condition can occur naturally in response to low light conditions (to allow more light into the eye) or can be induced for medical reasons. Mydriasis is often used intentionally in ophthalmology during eye exams to provide a clearer view of the retina, optic nerve, and other structures inside the eye. It is essential for the diagnosis of various eye conditions, including glaucoma, diabetic retinopathy, and age-related macular degeneration (AMD).

Mydriasis can be induced using mydriatic agents, such as tropicamide, phenylephrine, or atropine, which relax the muscles around the pupil, causing it to dilate. While it is typically a temporary condition, mydriasis can also occur due to neurological disorders, eye trauma, or the effects of certain medications.

One of the key drivers of the mydriasis market is the growing demand for advanced ophthalmic diagnostic technologies. As medical imaging systems like fundus cameras, optical coherence tomography (OCT), and retinal imaging systems continue to improve, they require precise pupil dilation for optimal performance.

These technologies provide high-resolution images of the retina, optic nerve, and other critical structures inside the eye, which are essential for diagnosing a variety of eye diseases such as glaucoma, diabetic retinopathy, and macular degeneration. Mydriasis is crucial for obtaining clear, accurate images during these diagnostic procedures, which is driving the increased demand for mydriatic agents that induce pupil dilation. As these diagnostic tools become more widespread and more efficient, the need for mydriatic drugs continues to grow, significantly contributing to the expansion of the mydriasis market. Additionally, the rising prevalence of chronic eye conditions and the aging global population further fuel the demand for pupil dilation in routine eye exams, making mydriasis a critical component of modern ophthalmic care.

Despite the growth of the Mydriasis market, several challenges continue to hinder its progress. One of the primary challenges is the side effects and safety concerns associated with mydriatic agents. While these agents are effective in inducing pupil dilation for diagnostic purposes, they can cause ocular discomfort, increased intraocular pressure, photophobia (sensitivity to light), and blurred vision. In some cases, they may also cause systemic side effects, such as increased heart rate or high blood pressure, particularly in individuals with underlying health conditions like hypertension or cardiovascular diseases.

Additionally, there is a risk of over-dilation, which can complicate the diagnostic process or lead to adverse effects during subsequent treatment. Some patients, especially the elderly or those with diabetes or glaucoma, may experience difficulty with the dilation process, potentially requiring additional monitoring or adjustments.

These safety concerns limit the widespread use of mydriatic agents, especially in vulnerable patient populations, and may slow the adoption of certain types of mydriatic treatments. This challenge underscores the need for safer, more effective alternatives that can minimize side effects while still achieving the necessary level of pupil dilation for diagnostic procedures.

The global Mydriasis market is highly competitive, with several leading companies driving innovation and market growth. Companies such as Viatris Inc., Opus Genetics, Eyenovia, Inc., Rayner Surgical Group Limited, Omeros Corporation, Alcon Inc., Novartis AG, Pfizer Inc., Akorn, Inc., and AbbVie Inc. are at the forefront of advancing technologies and developing mydriatic agents to address the growing demand for ophthalmic diagnostics.

These companies are investing heavily in research and development (R&D), focusing on improving the efficacy, safety, and patient experience of mydriatic treatments. Furthermore, strategic partnerships, acquisitions, and expanding product portfolios are helping these companies maintain a competitive edge and expand their market presence. As ophthalmic imaging technologies like fundus cameras and optical coherence tomography (OCT) continue to evolve, these companies are poised to play a crucial role in shaping the future of mydriasis in the global market.

Market Segmentation:

Segmentation 1: by Region

The global Mydriasis market is undergoing significant transformation, fuelled by several key factors that are reshaping the landscape of ophthalmic diagnostics. First, the rapid advancements in imaging technologies such as fundus cameras and optical coherence tomography (OCT) are revolutionizing the way ophthalmologists examine the retina and optic nerve. These technologies require precise pupil dilation to capture high-resolution, detailed images, driving the demand for effective mydriatic agents.

Second, the rising prevalence of chronic eye conditions, including glaucoma, diabetic retinopathy, and cataracts, is significantly increasing the need for regular diagnostic procedures involving mydriasis. As the global population ages, particularly in developed countries, there is a greater need for early detection and management of these conditions to prevent permanent vision loss.

Moreover, the expansion of healthcare access in emerging markets is further accelerating market growth. As access to modern diagnostic tools improves, particularly in regions such as Asia-Pacific and Latin America, more patients are undergoing eye exams that require pupil dilation.

Finally, the growing emphasis on personalized medicine and precision diagnostics in ophthalmology is driving innovation in mydriasis treatments. Companies are developing safer, faster acting mydriatic agents tailored to individual patient needs, ensuring more efficient and comfortable eye exams. These factors are all contributing to the ongoing transformation of the mydriasis market, making it a dynamic and fast-evolving sector in the global healthcare landscape.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Mydriasis Market: Industry Outlook

2. Global Mydriasis Market (Region), ($Billion), 2023-2035

3. Global Mydriasis Market: Competitive Landscape and Company Profiles

4. Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â